Formulated PSTA Injection Versus PATA Alone in the Management of Macular Edema Secondary to Non-ischemic Retinal Vein Occlusions

Al-Azhar University78 enrolled

Overview

The aim of this study is to compare formulated Posterior Subtenon Triamcinolone acetonide (PSTA) injection versus Posterior Subtenon Triamcinolone acetonide alone in the management of macular edema secondary to non-ischemic retinal vein occlusions, either central or branch.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Macula Edema

Interventions

Triamcinolone Acetonide and sodium hyaluronate and chondroitin sulfateDRUG

formulated with sodium hyaluronate and chondroitin sulfate

Triamcinolone Acetonide aloneDRUG

Triamcinolone Acetonide alone

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diminution vision due to macular edema secondary to non-ischemic retinal vein occlusions, either central or branch, as evidenced by clinical and angiographic evaluation * CMT ≥ 250 µ. * Willing to participate in the study Exclusion Criteria: * Unwilling to participate in the study. * Ischemic RVO * Prior laser treatment * Glaucoma/Ocular Hypertension * Cataract which lead to difficulty in the evaluation of macula * Vitreous hemorrhage * Macular ischemia * Iris neovascularisation * patients with intravitreal injection of anti VEGFs, steroid, or any intraocular surgery 3 months prior to the inclusion.

Locations (1)

Ehab tharwat

Damietta, New Damietta, Egypt

Outcomes

Primary Outcomes

Best-corrected visual acuity (BCVA)

will be measured with the Snellen chart

Time frame: Baseline

Best-corrected visual acuity (BCVA)

will be measured with the Snellen chart

Time frame: at 1st month

Best-corrected visual acuity (BCVA)

will be measured with the Snellen chart

Time frame: at 3rd month

Best-corrected visual acuity (BCVA)

will be measured with the Snellen chart

Time frame: at 6th month

central macular thickness ( CMT)

CMT will be measured with OCT

Time frame: at baseline

central macular thickness ( CMT)

CMT will be measured with OCT

Time frame: at 1st month

central macular thickness ( CMT)

CMT will be measured with OCT

Time frame: at 3rd month

central macular thickness ( CMT)

CMT will be measured with OCT

Time frame: at 6th month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.